Research programme: cannabinoid-based microencapsulated cell therapies - PharmaCyte Biotech

Drug Profile

Research programme: cannabinoid-based microencapsulated cell therapies - PharmaCyte Biotech

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nuvilex
  • Developer PharmaCyte Biotech; University of Northern Colorado
  • Class Cannabinoids; Cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Pancreatic cancer
  • Research Cancer

Most Recent Events

  • 01 Sep 2016 Preclinical trials in Brain and Pancreatic cancer in USA (Parenteral)
  • 15 Jun 2015 The University of Northern Colorado obtains a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) to continue development of cannabinoid-based microencapsulated therapies
  • 16 Mar 2015 Early research in Brain cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top